Banh, Robert S.
Kim, Esther S.
Spillier, Quentin
Biancur, Douglas E.
Yamamoto, Keisuke http://orcid.org/0000-0002-6323-9540
Sohn, Albert S. W.
Shi, Guangbin
Jones, Drew R.
Kimmelman, Alec C.
Pacold, Michael E. http://orcid.org/0000-0003-3688-2378
Article History
Received: 2 June 2020
Accepted: 29 July 2021
First Online: 1 September 2021
Competing interests
: A.C.K. has financial interests in Vescor Therapeutics, LLC. A.C.K. is an inventor on patents pertaining to KRAS-regulated metabolic pathways, redox control pathways in pancreatic cancer, targeting GOT1 as a therapeutic approach, and the autophagic control of iron metabolism. A.C.K is on the SAB of Rafael/Cornerstone Pharmaceuticals. A.C.K has been a consultant for Diciphera Pharmaceuticals. M.E.P. has options in Raze Therapeutics, is the recipient of travel funds from Thermo Fisher Scientific and consulted for aMoon Ventures. R.S.B., Q.S., and M.E.P. are co-inventors on a patent filing on aspects of CoQ10 metabolism. The other authors declare no competing interests.